VG Life Sciences, Inc. Provides Additional Insight Into Clinical Trial
Published: Dec 06, 2012
SAN MARINO, Calif.--(BUSINESS WIRE)--VG Life Sciences (OTC Pink: VRALD) (formerly known as Viral Genetics) has released its November 2012 Letter to Shareholders, published in its entirety below. In the letter as released to account for certain new developments, the Company’s President, Haig Keledjian, offers insight into the Company’s name change, recent restructuring, and an important milestone update into the Company’s Phase 1 physician-initiated clinical trial for ovarian cancer, and also other operational details.